iOnctura commences randomized Phase I/ II study in non-small cell lung cancer

iOnctura United States of America United Kingdom

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemoStudy will evaluate safety of the combination and explore whether targeting PI3K? with immunotherapy may rebalance the immune system to prevent or reverse resistance to current standard immunotherapy/chemo in NSCLCView original content:https://www.prnewswire.co.uk/news-releases/ionctura-commences-randomized-phase-iii-study-in-non-small-cell-lung-cancer-302449072.html